3D Medicines

What 3D Medicines does

3D Medicines (思路迪诊断/3DMed Diagnostics) is a China-headquartered precision oncology and infectious disease diagnostics company founded in 2010 by Dr. Xiong Lei and headquartered in Minhang District, Shanghai. The diagnostic business was carved out from the 3D Medicines Group in 2019 and operates through wholly-owned subsidiaries including the CAP/CLIA/ISO 15189-certified Shanghai 3DMed Medical Laboratory, 3D Medicines Biomedical Technologies INC. (Fremont, California), and an R&D presence in Singapore. The firmographic record associates the parent with a Hong Kong listing (hkg:1244), while the diagnostic entity's funding history is described as private equity rounds totaling approximately 1.78 billion RMB (≈$250M) across a 2019 seed and a 2021 Series B led by CPE. The company serves 800+ hospitals across China with a sales network covering 70%+ of core tertiary hospitals, and reports product reach across 70+ countries.

Name

3D Medicines

Legal name

3D Biomedicine Science & Technology Co., Limited

Website

https://3dmedcare.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

3D Medicines (3DMed Diagnostics) is a China-based precision diagnostics company that develops automated NGS instruments (ANDiS series), exosome-based IVD kits (notably 泌思优 for ovarian cancer), and AI pathology software, serving 800+ hospitals and exporting to 70+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. IVD Devices and Reagents: Sale of in vitro diagnostic instruments and reagents including automated NGS library preparation equipment (ANDiS series), COVID-19 and infectious disease test kits, tumor diagnostic reagents. One-time product sales model with consumables recurring revenue.
2. Third-Party Medical Testing Services (LDT): Molecular diagnostic testing services through Shanghai 3DMed Medical Laboratory, providing tumor early diagnosis, companion diagnosis, and dynamic monitoring services. Laboratory-developed testing services for hospitals and pharmaceutical companies.
3. Pharmaceutical Company Cooperation: Companion diagnostics development partnership with pharmaceutical companies for drug co-development and patient enrollment services. Strategic collaboration for CDx (companion diagnostics) development.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

3D Medicines develops, manufactures, and sells in vitro diagnostic (IVD) instruments and reagent kits focused on molecular diagnostics for oncology and infectious disease. Its portfolio spans the ANDiS series of automated nucleic acid extraction and NGS library preparation systems, exosome-based ovarian cancer diagnostics, COVID-19 qPCR tests, and DNA/RNA-NGS co-detection reagents, complemented by AI-driven pathology image analysis software. The company also runs a CAP/CLIA/ISO15189-certified medical laboratory providing third-party LDT molecular diagnostic testing services.

Product overview

3D Medicines (思路迪诊断) offers a comprehensive precision diagnostics platform centered on automated molecular diagnostic instruments, IVD reagent kits, and AI-powered bioinformatics software for cancer and infectious disease diagnostics. The product portfolio includes: (1) Automated nucleic acid extraction and library preparation systems (ANDiS series: 350, 355, 396, 500, 3150, 3200, 8000S) that provide end-to-end workflow automation from sample processing to sequencing; (2) IVD diagnostic products including the global first exosome-based ovarian cancer test (泌思优), COVID-19 and combination flu tests, and DNA/RNA-NGS co-detection reagents; (3) AI-powered pathology image analysis platform (APiLab) with AP-PI and AP-TIME modules for tumor biomarker quantification; (4) Bioinformatics software including TiNA for pathogen genomic analysis and automated cancer NGS data analysis. The company operates through LDT (Laboratory Developed Test) services via its CAP/CLIA/ISO15189-certified medical laboratory, serving over 800 hospitals across China.

Differentiator

Problem solved

Functional benefit

Brands

• 泌思优 (Mi Si You): World's first exosome-based ovarian cancer in vitro diagnostic product. Registered name: Human Exosome CA125, HE4, C5a Detection Reagent Kit (Chemiluminescence Method). Product registration: 国械注准20243400138.
• 书答科技 (ShuDa Technology)
• ANDiS
• APiLab
• APTime
• DR靶向通
• TiNA (TINA)

Products and services

• 3DMed Automated Cancer NGS Solution End-to-end automated cancer NGS solution providing nucleic acid extraction, library preparation, sequencing data analysis, variant interpretation and automated report generation for clinical laboratories with limited NGS experience.
• ANDiS 8000S Laboratory Testing Assembly Line Solution Fully automated intelligent laboratory assembly line for large-scale nucleic acid testing, with maximum throughput of 8,000 samples per 24 hours and minimum reporting time of 1.5 hours, processing sample splitting, nucleic acid extraction, reagent addition, QC setup, PCR reaction preparation and amplification analysis.
• ANDiS 500 Fully Automated Closed Gene Sequencing Library Preparation System China's first NMPA-approved fully automated closed NGS library preparation instrument with Class II medical device certification, using single-sample closed cartridge mode to avoid cross-contamination, completing library preparation in 3.5 hours with only 3 manual steps.
• ANDiS 350/355/396 Automated Nucleic Acid Extraction Systems Automated magnetic bead-based nucleic acid extraction instruments for clinical samples, with ANDiS 350 processing up to 32 samples per run and ANDiS 396/355 processing up to 96 samples per run with extraction times as fast as 8-20 minutes.
• ANDiS 3150/3200 Automated Sample Pre-processing Systems Automated workstations for sample tube barcode scanning, decapping, pipetting, and recapping with ANDiS 3150 processing 96 samples in 12 minutes across 4 independent channels, and ANDiS 3200 providing high-throughput sample processing for nucleic acid testing laboratories.
• 泌思优 (Mi Si You) Human Exosome CA125, HE4, C5a Detection Kit World's first exosome-based ovarian cancer in vitro diagnostic product measuring CA125, HE4, and C5a from serum exosomes for epithelial ovarian cancer auxiliary diagnosis, achieving 95.5% sensitivity and 90.2% specificity with 89.7% Stage I sensitivity.
• 30-Minute Rapid COVID-19 Nucleic Acid Detection Kit Rapid COVID-19 nucleic acid detection kit using fluorescent PCR method that reduces amplification time from 80-120 minutes to 30 minutes while maintaining detection sensitivity of 200 copies/mL, approved by NMPA.
• COVID-19 + Influenza A/B Combination Nucleic Acid Detection Kit First domestic COVID-19 + Influenza A/B combination test kit using fluorescent PCR platform for differential diagnosis of COVID-19 and influenza infections, NMPA approved.
• DNA/RNA-NGS Synchronous Co-detection Ready-to-use Reagent Kit (DR靶向通) DNA and RNA simultaneous co-detection reagent kit for solid tumor driver gene testing that detects DNA mutations/Indels and RNA fusion genes from the same sample in a unified workflow, improving fusion gene detection by 11.7-18.1% compared to DNA-based NGS alone.
• APiLab Tumor Pathology AI Platform AI-powered tumor pathology image analysis platform including AP-PI for automated PD-L1 IHC image quantitative analysis and AP-TIME for multi-plex fluorescent IHC visualization analysis, achieving 95% AI-pathologist consistency in clinical validation.
• TiNA SARS-CoV-2 Testing Information Intelligent Management Platform Genomic data analysis system for SARS-CoV-2 providing virus detection, variant detection and annotation, and whole genome consensus sequence generation for strain typing, with dynamic software updates as new variants emerge.

Quantifiable outcome

• Ovarian cancer early diagnosis sensitivity of 95.5%, specificity of 90.2%, and 89.7% sensitivity for Stage I ovarian cancer (vs. 27.8-64.3% for traditional CA125)
• +4 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Five partnerships are on record, tiered major and core.

• Chinese Medical Association Pathology Branch and National Clinical Pathology Quality Control CentermajorStrategic or Co-development Partner · 16 July 2025Jointly published the first expert consensus on DNA and RNA co-detection for solid tumor common driver genes in China.
• MGI (华大智造)coreTechnology or Integration · 13 June 2025Strategic partnership focused on IVD precision medicine combining MGI's high-throughput sequencing platform with 3D Medicines' diagnostic solutions. Integrates sample extraction, library construction, high-throughput sequencing, and data analysis for comprehensive testing solutions.
• Shanghai Jiao Tong University Affiliated Chest Hospital (上海交通大学附属胸科医院)majorStrategic or Co-development Partner · 1 November 2023Expert workstation collaboration with Prof. Han Yuchen to establish tumor pathology automated analysis system and clinical validation.
• Roche (罗氏)coreStrategic or Co-development Partner · 15 June 2023Diagnosis-treatment integration partnership to create integrated patient care pathways from screening, diagnosis to treatment decision support. Jointly exploring automated and intelligent solutions for precision medicine adoption.
• Lingang Group (临港集团)majorStrategic or Co-development Partner · 1 May 2022Established the first in-area 'sampling and testing on-site' professional medical testing institution at Lingang New Area, achieving 10,000 single-tube/day testing capacity, expandable to 100,000/day.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Illumina: Global leader in NGS sequencing platforms and reagents. Indirectly comparable as the underlying sequencing technology provider whose platforms 3D Medicines' automated library prep instruments complement — but also a long-term platform threat.
• BGI Genomics: China's largest genomics company offering NGS sequencing services, IVD products, and sequencing platforms. Competes with 3D Medicines across sequencing services and is also a sequencing platform supplier (MGI sister entity).
• MGI Tech: Sequencing platform manufacturer and 3D Medicines' partner. Sells high-throughput sequencers and library prep automation that overlaps with ANDiS's automation niche and competes in the broader molecular diagnostics workflow.
• Roche Diagnostics: Global diagnostics leader and 3D Medicines' strategic partner. Competes broadly in oncology IVDs, companion diagnostics, and pathology while also partnering on integrated diagnosis-treatment ecosystems.

Direct peers

• Novogene: Major China-based NGS service provider with extensive hospital channel reach for tumor and reproductive health testing. Direct competitor in clinical NGS services and translational research support.
• Genetron Health: China-based precision oncology company offering NGS-based cancer screening, diagnosis, and monitoring services plus IVD products. Competes with 3D Medicines in hospital-channel NGS oncology diagnostics.
• Amoy Diagnostics: China-based molecular diagnostics company specializing in PCR and NGS-based oncology companion diagnostics and reagents. Directly competes in tumor mutation detection reagents and CDx development.
• Burning Rock Biotech: China-based NGS-focused oncology diagnostics company providing tumor NGS testing services and IVD products to hospitals. Closest direct competitor to 3D Medicines' tumor NGS clinical diagnostics business.

Emerging players

• Berry Genomics: China-based genetic testing company with NIPT heritage expanding into oncology NGS and liquid biopsy. Comparable in NGS-based tumor diagnostics targeting Chinese hospital customers.
• AnchorDx: China-based early-detection oncology diagnostics company developing methylated DNA and liquid biopsy tests. Competes in next-generation early cancer detection with focus on lung and other high-incidence cancers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/3DMedcare
• YouTubeyoutube.com/channel/UCOfwy7Y9JcC4YrCSgMRv1Dw
• Facebookfacebook.com/3DMedivd
• LinkedInlinkedin.com/company/9360556
• Instagraminstagram.com/3dmedivd

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds5 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3D Medicines